Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) has seen a stock price increase of nearly 5% during trading, attributed to recent regulatory approvals for its new drug developments [1] Group 1: Clinical Trials and Drug Approvals - The National Medical Products Administration (NMPA) has approved Dongyang Sunshine Pharmaceutical's self-developed first-class new drug, HECN30227, for clinical trials aimed at treating chronic hepatitis B [1] - The company has also received approval for the launch of Fingo Mod Capsules, marking it as the first domestic generic version, breaking the original research monopoly in the market [1] Group 2: Market Performance - As of the latest report, Dongyang Sunshine's stock is trading at 48.88 HKD, with a trading volume of 23.2866 million HKD [1]